Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Syndax Pharma (NQ: SNDX )

20.64 +0.39 (+1.90%)
Streaming Delayed Price Updated: 3:58 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Syndax Pharma

< Previous 1 2 3 Next >
81 Biggest Movers From Yesterday
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 11, 2021
Companies Reporting Before The Bell • Oxford Lane Capital (NASDAQ:OXLC) is estimated to report earnings for its fourth quarter. • ReWalk Robotics (NASDAQ:RWLK) is... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Evaxion Biotech (NASDAQ:EVAX) stock moved upwards by 157.5% to $16.74 during Thursday's regular session. Evaxion Biotech's stock is trading at a volume of... 
Via Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4... 
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Syndax Pharma, Incyte Ink Licensing Pact For Graft Vs. Host Disease Candidate
Syndax Pharmaceuticals Inc (NASDAQ: SNDX) and Incyte Corporation (NASDAQ: INCY) have entered into an exclusive worldwide collaboration and license... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Syndax Pharmaceuticals (NASDAQ:SNDX) shares moved upwards by 8.94% to $20.48 during Monday's pre-market session. The company's market cap stands at $995.9... 
Via Benzinga
Syndax Pharmaceuticals's Return On Capital Employed Insights
According to data from Benzinga Pro, during Q2, Syndax Pharmaceuticals's (NASDAQ:SNDX) reported sales totaled $379.00 thousand. Despite a 17.78% increase in earnings, the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers IVERIC bio (NASDAQ:ISEE) shares ... 
Via Benzinga
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Earnings Scheduled For August 9, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million. •... 
Via Benzinga
Syndax Pharmaceuticals: Return On Capital Employed Insights
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million... 
Via Benzinga
Return On Capital Employed Overview: Syndax Pharmaceuticals
In Q1, Syndax Pharmaceuticals (NASDAQ:SNDX) posted sales of $379.00 thousand. Earnings were up 36.77%, but Syndax Pharmaceuticals still reported an overall loss of $27.16 million... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
Syndax Pharma Updates On Interim Phase 1 Data From SNDX-5613 Leukemia Trial
Syndax Pharmaceuticals Inc (NASDAQ: SNDX), in its Q1 earnings, also announced new data from the ongoing Phase 1 dose-escalation portion of the Phase 1/2... 
Via Benzinga
Recap: Syndax Pharmaceuticals Q1 Earnings
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Minerva Neurosciences (NASDAQ:NERV 
Via Benzinga
Last Week's Notable Insider Buys: AppLovin, Bed Bath And Beyond, TuSimple And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs. Once again, some insiders took advantage of recent public... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Renalytix AI (NASDAQ:RNLX) shares rose 21.41% to $30.62 during Thursday's regular session. Renalytix AI's stock is trading at a volume of 1.0 million... 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
Exposures COVID-19 Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
46 Biggest Movers From Yesterday
Gainers Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) shares jumped 27.3% to close at $9.79 on Tuesday after the company reported inducement grants. The company recently said it... 
Via Benzinga
Why Syndax Pharmaceuticals Stock Is Sinking Today
The company announced results from an early-stage clinical study. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Tumbles 370 Points; Kansas City Southern Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded down 1.09% to 33,706 while the NASDAQ fell 1.30% to 13,733.94. The S&P also fell, dropping 0.97% to 4,122.80. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers MyMD Pharmaceuticals, Inc. - Common Stock (NASDAQ:MYMD) shares moved upwards by 14.12% to $5.1 during Tuesday's regular session. As of 12:31 EST, this security... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 1.8%; Futu Holdings Shares Plunge
Midway through trading Tuesday, the Dow traded down 0.68% to 33,846.89 while the NASDAQ fell 0.91% to 13,788.71. The S&P also fell, dropping 0.65% to 4,136.13. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
31 Stocks Moving In Tuesday's Mid-Day Session
Gainers MyMD Pharmaceuticals, Inc. (NASDAQ: MYMD) gained 20.8% to $5.32 after dropping more than 10% on Monday. Takung Art Co., Ltd. (NASDAQ: TKAT) shares surged 18.2% to $21.08... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; P&G Profit Tops Views
Following the market opening Tuesday, the Dow traded down 0.43% to 33,931.13 while the NASDAQ fell 0.22% to 13,883.52. The S&P also fell, dropping 0.27% to 4,151.87. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.